Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Radiopharm Theranostics Limited ( (AU:RAD) ) has shared an announcement.
Radiopharm Theranostics has announced a series of senior financial and corporate governance changes, with the resignation of Chief Financial Officer and Joint Company Secretary Phillip Hains. The company will continue to outsource core finance and secretarial functions to Acclime Australia, maintaining operational continuity while refreshing key personnel.
Under the ongoing services agreement with Acclime Australia, Aaron Laurita has been nominated as the new Chief Financial Officer, bringing a decade of finance and commercial experience across biotechnology and other sectors in Australia, the United States and Canada. In parallel, Amritha Sushil has been appointed Joint Company Secretary alongside incumbent Nathan Jong, strengthening the company’s governance and compliance framework with immediate effect.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals targeting areas of high unmet medical need. The Australia-based group concentrates on theranostic cancer treatments, positioning itself within the growing radiopharmaceuticals segment of the global oncology market.
Average Trading Volume: 3,414,416
Technical Sentiment Signal: Sell
Current Market Cap: A$70.88M
For a thorough assessment of RAD stock, go to TipRanks’ Stock Analysis page.